Publications – Fibronostics

Publications

Publications Highlight

Dynamics of Noninvasive Tests (NITs) – LIVERFASt, FIB-4 and Vibration-Controlled Transient Elastography (VCTE, FibroScan), During Monitoring Therapy with Resmetirom (RT) in Patients with MASH

LIVERFASt Outperforms FIB-4, in Sequential Combination with Vibration-Controlled Transient Elastography (VCTE) for Identifying ≥F3 Stages in Patients with MASLD Including Patients with Type 2 Diabetes (T2DM)

All Publications

Read our latest publications

LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM

Dynamics of NITs (LIVERFASt, FIB-4, VCTE) during monitoring therapy with Resmetirom in patients with MASH — update

Noninvasive initiation and monitoring of Resmetirom therapy using LIVERFASt, FIB-4 and VCTE in patients with MASH

Correlations between LIVERFASt, MRE for fibrosis assessment and ICFF for steatosis assessment in MASLD patients

The utility of NITs — LIVERFASt, FIB-4 and VCTE — in the initiation and monitoring of Resmetirom therapy in MASH patients (initial cohort)

Diagnostic performance of LIVERFASt as a non-invasive liver fibrosis test: data from three cohorts (JGLD manuscript)

Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D

Association between Psoriasis severity and steatosis measured by LIVERFASt

Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)

Combination of LIVERSTAT and Fibroscan-LSM outperforms FIB-4 and LSM for MASLD Advanced Fibrosis (F3F4) — multicenter

LIVERFASt identifies advanced (F3F4) and clinically significant fibrosis (F2-F4) especially well with Fibroscan in MASLD patients

Comparison of two non-invasive models for advanced fibrosis detection in T2D and MASLD using LiverSTAT, FIB-4 and LSM (Saudi Arabia)

Evaluation of LIVERFASt for staging fibrosis in MASLD patients in NIDDK studies using liver biopsy

LIVERSTAT first-line screening tool: MAFLD patients outperformed standard-of-care FIB-4 (training/validation)

Recommended Clinical Care Pathway with FIB-4 underestimates the prevalence of Advanced Fibrosis, compared to sequential CCP with LIVERSTAT and LSM (NHANES)

LIVERSTAT as NIT for risk stratification for MAFLD — a single-centre study using liver biopsy as reference standard (Malaysia)

Fasting vs non-fasting: assessment of the impact on LIVERSTAT

LIVERFASt-LFS NIT for Fatty Liver Disease, for Primary Care Provider (PCP) screening

Assessment of Fatty Liver Disease using LIVERFASt in South-East Asia (real-world evidence)

Predictive Value of LIVERFASt, ARFI-FIB-4 to identify chronic Hepatitis B (CHB) — NUH Singapore cohort

Comparative Performances of LIVERFASt, Fibroscan and other NITs for severe fibrosis in NAFLD patients (Bordeaux cohort)

Simulating clinical confidence intervals for black-box algorithmic predictions of liver steatosis

Comparison analysis of FIB-4, LIVERFASt, LSM in Sequential and Combinatory Pathways for NAFLD

Long-term prognosis of MAFLD patients according to non-invasive methods

Noninvasive LIVERFASt transition rate to liver fibrosis, similar to liver biopsy in NAFLD patients

Repeated noninvasive liver biopsy surrogate LIVERFASt correlates with BMI and liver enzyme improvements

Comparative Assessment of NIMs (LIVERFASt/ELF/FIB-4/LSM) in a prospective cohort with chronic liver diseases (Thailand)

Application of LIVERFASt biomarkers to evaluate longitudinal hepatic fibrosis and inflammation after HCV cure

Application of LIVERFASt to predict steatosis in Chronic Hepatitis B patients with metabolic syndrome

LIVERFASt Demonstrates the Feasibility of a Screening Program for MASLD